Compass Therapeutics, Inc. announced that its Board of Directors has appointed Thomas Schuetz, M.D., Ph.D., President of Research and Development and Vice Chair of the Board of Directors of the Company, as President and Chief Executive Officer of the Company, effective May 28, 2024. Vered Bisker-Leib, Ph.D., M.B.A., has stepped down as Chief Executive Officer and as a member of the Board of Directors of the Company, effective May 28, 2024. Dr. Bisker-Leib will continue to be available to the Company as a Senior Consultant for the next 15 months.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8 USD | -2.44% | -20.00% | -48.72% |
Jul. 01 | Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 2000 Growth Index | CI |
Jul. 01 | Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell Microcap Growth Index | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-48.72% | 110M | |
+16.61% | 122B | |
+17.75% | 112B | |
+17.23% | 25.91B | |
-24.11% | 19.33B | |
-18.56% | 16.17B | |
-18.47% | 15.6B | |
-47.75% | 14.65B | |
+57.35% | 14.34B | |
+5.62% | 14B |
- Stock Market
- Equities
- CMPX Stock
- News Compass Therapeutics, Inc.
- Compass Therapeutics, Inc. Announces CEO Changes